US at a glance
- Population
- 341.8 million 2025
- Life expectancy at birth
- 78.9 years, 2024
- People aged 65 and over
- 18.4 % of people, 2025
- Health spending per person
- 13,473 US$ per person, 2023
- Doctors
- 3.68 per 1,000 people, 2022
Updated
Reviewed by Vidhi Upadhyay
US Neurorehabilitation Devices Market Industry Trends and Forecast to 2034: Segmented by (Product, Condition, End User, Region) - Growth, Market Size, Future Prospects & Competitive Analysis, 2024-2034
Values shown here are placeholder estimates, not researched figures. Researched 2024 historical, 2025 base-year and 2026–2034 forecast values are prepared with the full report.
Source: Acuitas Health Analytics. Full methods, sources and usage terms come with report purchase.
$883.1 Mn total, 2026–2034
| Year | Market size | Change that year | Since 2025 |
|---|---|---|---|
| 2024 (estimate) | $702.7 Mn | — | — |
| 2025 (base) | $765.3 Mn | +$62.5 Mn | — |
| 2026 (forecast) | $833.4 Mn | +$68.1 Mn | +8.9% |
| 2027 (forecast) | $907.6 Mn | +$74.2 Mn | +18.6% |
| 2028 (forecast) | $988.3 Mn | +$80.8 Mn | +29.1% |
| 2029 (forecast) | $1.08 Bn | +$88.0 Mn | +40.6% |
| 2030 (forecast) | $1.17 Bn | +$95.8 Mn | +53.2% |
| 2031 (forecast) | $1.28 Bn | +$104.3 Mn | +66.8% |
| 2032 (forecast) | $1.39 Bn | +$113.6 Mn | +81.6% |
| 2033 (forecast) | $1.51 Bn | +$123.7 Mn | +97.8% |
| 2034 (forecast) | $1.65 Bn | +$134.7 Mn | +115.4% |
Placeholder estimates. Each year is projected from our earlier market estimate and its CAGR. Researched values come with the full report.
| Market size, 2025 | $765.3 Mn placeholder estimate |
|---|---|
| Forecast, 2034 | $1.65 Bn placeholder estimate |
| Growth (CAGR), 2025–2034 | 8.9% placeholder estimate |
| Years | 2024 historical · 2025 base year · 2026–2034 forecast |
| Segments | Product, condition and end user (see all) |
| Key players | Hocoma (DIH), Ekso Bionics, ReWalk Robotics, Bioness, MindMaze (see all) |
| Regulator in the US | FDASource: US Food and Drug Administration. Checked 14 Nov 2026. |
| Formats | PDF, PPTX, XLSX |
Sizes and growth here are placeholder estimates, not researched figures. Researched figures come with the full report.
Neurorehabilitation devices help people recover movement after stroke or brain injury, using robots, stimulation and virtual reality.
Key segments of the neurorehabilitation Devices market include product (Rehabilitation Robots, Brain Stimulation Devices and Wearable Sensors) and condition (Stroke, Spinal Cord Injury and Traumatic Brain Injury).
An ageing population, more people living with brain and nerve diseases, better diagnosis and the first disease-modifying treatments are driving the neurorehabilitation Devices market.
Biomarker-guided treatment, earlier diagnosis and new device-based therapies give the neurorehabilitation Devices market strong room to grow.
Hard-to-reach brain targets, high failure rates in trials, side effects and high prices for new therapies hold back the neurorehabilitation Devices market.
The neurorehabilitation Devices market is moderately concentrated. Leading companies compete on product innovation, clinical evidence, pricing and geographic reach, and use partnerships and acquisitions to expand their portfolios.
The FDA clears or approves medical devices by risk class, through 510(k) clearance, De Novo classification or premarket approval (PMA).[1] Medicare covers people aged 65 and over and some younger people with disabilities, and Medicaid covers many people on low incomes; both are run with the Centers for Medicare & Medicaid Services (CMS).[2]
[1] US Food and Drug Administration. Checked 14 Nov 2026.
[2] Centers for Medicare & Medicaid Services. Checked 14 Nov 2026.
Medical device rules, such as the US FDA 510(k) and PMA pathways and the EU Medical Device Regulation, govern how neurorehabilitation Devices products are approved and monitored. Reimbursement codes and hospital purchasing policies decide how widely they are used in the US.
What doctors and scientists are doing in Neurorehabilitation Devices right now, from free public sources.
Sources: PubMed (US National Library of Medicine), ClinicalTrials.gov, World Bank. Fetched 12 Nov 2026. Papers and trials are found by search words, so the counts are a guide. Titles only; read each paper at its source.
[1] World Bank Open Data, Health spending per person (US$ per person). Retrieved 19 Nov 2026.
[2] World Bank Open Data, Doctors (per 1,000 people). Retrieved 19 Nov 2026.
[3] World Bank Open Data, People aged 65 and over (% of people). Retrieved 19 Nov 2026.
From our blog
US · 1 shared keyword
US
US
US
US
US
Digital Health · US
Pharmaceuticals · US
Pharmaceuticals · US
Healthcare Services · US
Pharmaceuticals · US
Pharmaceuticals · US